Dubai Investments PJSC

The disclosure clarifies the process for shareholders to delegate someone to attend the General Assembly on their behalf. Shareholders can delegate individuals who are not board members, company staff, or employees of a securities brokerage company. The delegated person can represent multiple shareholders but cannot exceed 5% of the company's issued capital. Legal representatives must represent those lacking legal capacity. The shareholder's signature on the power of attorney must be approved by specific entities such as a Notary Public, Chamber of Commerce, a bank where the shareholder has an account, licensed financial markets, or any licensed notarial entity in the UAE. The proxy form should include the shareholder's name, contact number, and the approving authority. For further inquiries, contact details are provided.

Dubai Investments PJSC reported a net profit before tax of AED 1.3 billion for the fiscal year ending December 31, 2024, marking a 21% increase from the previous year. The company's total income reached AED 4.66 billion, driven by strong real estate sales and increased rental income. Total assets grew to AED 22.10 billion by the end of 2024. The board proposed an 18% cash dividend for 2024, reflecting a commitment to shareholder value. The company plans to focus on growth by evaluating investment opportunities, strategic divestments, and potential IPOs to enhance market presence and shareholder value.

Dubai Investments announced that its subsidiaries, GlobalPharma and Emirates Float Glass (EFG), have signed Memorandums of Understanding (MOUs) during a meeting in Doha, Qatar, aimed at promoting industrial growth and sustainable development. The agreements, supported by the Ministry of Industry and Advanced Technology, involve collaboration with various regional partners. GlobalPharma signed an MOU with Morocco's Zenith Pharma to enhance pharmaceutical production, focusing on critical medications, with an investment of over $50 million. Emirates Float Glass signed an MOU to supply float glass to a regional company, enhancing cooperation in the glass manufacturing sector. GlobalPharma was recognized for its contributions to pharmaceutical research and development.

Dubai Investments has announced the launch of Asayel Avenue, a new residential cluster in the Mirdif Hills development in Dubai. Asayel Avenue will feature 193 residential units, including 1, 2, and 3-bedroom apartments, designed to offer luxury, functionality, and larger living spaces with enhanced natural light. The project, with an investment of AED 400 million, is set to begin construction in Q2 2025 and complete by Q2 2027. It aims to set new standards for community-focused living in Dubai, with amenities such as fitness centers, recreational areas, and smart living solutions. The development emphasizes green integration and balanced lifestyles, catering to the demand for premium residential options in the city.

Globalpharma, a leading pharmaceutical company in the UAE and a subsidiary of Dubai Investments PJSC, plans to launch 25 new products in 2025 across therapeutic areas such as diabetes, cardiovascular, gastroenterology, and orthopaedics. This initiative is part of Globalpharma's strategy to provide high-quality and accessible medications to meet regional healthcare needs. The company aims to strengthen its distribution network and form new partnerships to ensure product accessibility and meet the needs of healthcare practitioners and patients. Globalpharma's focus for 2025 includes innovation, accessibility, and partnerships, building on the success of previous product launches in 2024. The company's efforts align with Dubai Investments' vision to transform key industries and establish a strong presence in the global pharmaceutical sector.